Clinical Trial Update: A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a biosimilar insulin degludec/insulin aspart (22011) vs Ryzodeg in adults with type 2 diabetes in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin degludec/insulin aspart biosimilar (22011)
• Ryzodeg (insulin degludec/insulin aspart)

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Diabetes | Phase 3 | Status: UNKNOWN